Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach

Yixin Wang, Jun Li, Ravi Anupindi

Research output: Contribution to journalArticlepeer-review

Abstract

Understanding the drivers of market concentration in the generic pharmaceutical industry is essential to guaranteeing the availability of low-cost generics. In this paper, we develop a structural model to capture the multiple determinants governing manufacturers’ entry decisions; in particular, we focus on how manufacturing complexity and the regulatory environment for generics approval affect concentration in drug markets. We estimate the model using data collated from six disparate sources. We find that manufacturing complexity, as reflected in the number of active ingredients, for example, significantly reduces the likelihood of generics entry. Moreover, the delay in the review process for the generics applications significantly affects the number of firms entering a market. Our policy simulations suggest that a shortened drug approval review time significantly increases the average number of entrants per market and reduces the fraction of markets with no generics entry; however, a notable portion of markets would still lack any generic competition.

Original languageEnglish (US)
Pages (from-to)1449-1467
Number of pages19
JournalManagement Science
Volume69
Issue number3
DOIs
StatePublished - Mar 2023
Externally publishedYes

Keywords

  • government: regulations
  • market entry decision
  • structural modeling

ASJC Scopus subject areas

  • Strategy and Management
  • Management Science and Operations Research

Fingerprint

Dive into the research topics of 'Manufacturing and Regulatory Barriers to Generic Drug Competition: A Structural Model Approach'. Together they form a unique fingerprint.

Cite this